UNSPSC 51286001: Dichlorophenarsine

This classification denotes an anti-infective agent with the molecular formula C6H6AsCl2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3WD5400T9N, chemically known as phenol, 2-amino-4- (dichloroarsino)-, hydrochloride but more generally known as dichlorophenarsine, which bears US NIH Compound Identifier 68302. European Medicines Agency schedules Dichlorophenarsine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07086MIG. The term DICHLOROPHENARSINE is an International Non-Proprietary Name.

DICHLOROPHENARSINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: [AS](CL)(CL)C1CC(N)C(O)CC1.

UNSPSC 51286001 Dichlorophenarsine, a Commodity code, shows little relevant recent activity in state and local procurement. The two most recent opportunities posted under this code—a piggyback pharmaceutical warehouse order from the Illinois Department of Public Health and a Seminole County, Florida purchase of Naloxone and drug deactivation systems—do not align with the nominal scope of dichlorophenarsine procurement. The Illinois contract, awarded to Chartwell Rx LLC on August 28, 2026, supplied Doxycycline Hyclate and Ciprofloxacin Hydrochloride totaling $2.99 million over three years, while the Seminole County solicitation (IFB 60459723LAS, due July 26, 2023) sought Naloxone and deactivation equipment for community health. Neither opportunity involves dichlorophenarsine as a product line.

The code's recent posting volume does not support pursuit. Buyers soliciting under this code include state health departments and county health authorities, typically using cooperative purchasing consortia (MMCAP Infuse) or competitive IFB processes. Geographic activity is limited to Illinois and Florida in the available records, with no clear pattern of ongoing procurement activity under the dichlorophenarsine classification. The mismatch between the code's nominal scope and the actual products being acquired suggests either miscoding by issuing bodies or minimal genuine demand for dichlorophenarsine in state and local markets. Watch activity for any future solicitations that actually name dichlorophenarsine as a requirement; skip pursuit unless a properly coded opportunity emerges.